{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:42:03Z","timestamp":1793295723615,"version":"4.5.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100012173","name":"China-Japan Friendship Hospital","doi-asserted-by":"publisher","award":["ZRJY2023-GG02"],"award-info":[{"award-number":["ZRJY2023-GG02"]}],"id":[{"id":"10.13039\/501100012173","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018684","name":"National Health Commission of the People\u2019s Republic of China","doi-asserted-by":"crossref","award":["2022-NHLHCRF-YS-02"],"award-info":[{"award-number":["2022-NHLHCRF-YS-02"]}],"id":[{"id":"10.13039\/501100018684","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Patients with anti-threonyl (PL7) positive anti-synthetase syndrome (ASS) exhibit a high prevalence of interstitial lung disease (ILD), which can progress to progressive pulmonary fibrosis (PPF) and increased mortality. This study aims to explore the clinical characteristics, imaging features and predictive factors for PPF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective cohort of PL7-ASS patients at a single tertiary centre between January 2018 and December 2022 was analysed. Clinical, serological and radiological data were collected at baseline and during follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study included 69 PL7-ASS patients with ILD (mean age: 54.5\u2009years; 73.9% female). Baseline CT imaging revealed the following patterns: cellular non-specific interstitial pneumonia (cNSIP, 29%), fibrotic NSIP (fNSIP, 18.8%), organizing pneumonia (OP, 14.5%), OP-cNSIP overlap (15.9%), OP-fNSIP overlap (14.5%) and usual interstitial pneumonia (UIP, 7.2%). PPF developed in 39.1% of patients. Elevated levels of lactate dehydrogenase (LDH; HR\u2009=\u20091.021, 95% CI: 1.002\u20131.04, P\u2009=\u20090.031) and carbohydrate antigen 125 (CA125; HR\u2009=\u20091.164, 95% CI: 1.023\u20131.326, P\u2009=\u20090.022) were identified as independent predictors of PPF. Patients with UIP or OP-NSIP overlap patterns exhibited worse survival (P\u2009=\u20090.0479) and higher PPF prevalence (P\u2009=\u20090.029). Patients who developed PPF had significantly lower survival rates compared with those without PPF (HR\u2009=\u20095.120, 95% CI: 1.566\u201316.740, P\u2009=\u20090.018).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>PL7-ASS patients with ILD are at significant risk of developing PPF, which is associated with poor survival outcomes. Elevated LDH and CA125 levels may serve as reliable predictors of PPF, highlighting the importance of early identification and aggressive management strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaf306","type":"journal-article","created":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T07:22:21Z","timestamp":1748848941000},"page":"5379-5387","source":"Crossref","is-referenced-by-count":5,"title":["Predictive factors and clinical outcomes of progressive pulmonary fibrosis in anti-threonyl (PL7) positive anti-synthetase syndrome"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-8740-6271","authenticated-orcid":false,"given":"Xueyan","family":"Shan","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Guang\u2019anmen Hospital, China Academy of Chinese Medical Sciences , Beijing,","place":["China"]},{"name":"Graduate school, Beijing University of Chinese Medicine , Beijing,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenguo","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Radiology, China-Japan Friendship Hospital , Beijing,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guochun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, The Key Laboratory of Myositis, China-Japan Friendship Hospital , Beijing,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3674-9307","authenticated-orcid":false,"given":"Yongpeng","family":"Ge","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, The Key Laboratory of Myositis, China-Japan Friendship Hospital , Beijing,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,3]]},"reference":[{"key":"2025100315132778900_keaf306-B1","doi-asserted-by":"crossref","first-page":"866087","DOI":"10.3389\/fimmu.2022.866087","article-title":"Aminoacyl-tRNA synthetases: on anti-synthetase syndrome and beyond","volume":"13","author":"Galindo-Feria","year":"2022","journal-title":"Front Immunol"},{"key":"2025100315132778900_keaf306-B2","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.3390\/jcm8112013","article-title":"Influence of antisynthetase antibodies specificities on antisynthetase syndrome clinical spectrum time course","volume":"8","author":"Cavagna","year":"2019","journal-title":"J Clin Med"},{"key":"2025100315132778900_keaf306-B3","doi-asserted-by":"crossref","first-page":"5556","DOI":"10.21037\/jtd-20-3328","article-title":"A narrative review of interstitial lung disease in anti-synthetase syndrome: a clinical approach","volume":"13","author":"Sawal","year":"2021","journal-title":"J Thorac Dis"},{"key":"2025100315132778900_keaf306-B4","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.autrev.2012.06.006","article-title":"Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity","volume":"12","author":"Hervier","year":"2012","journal-title":"Autoimmun Rev"},{"key":"2025100315132778900_keaf306-B5","doi-asserted-by":"crossref","first-page":"106579","DOI":"10.1016\/j.rmed.2021.106579","article-title":"Predictors for progressive fibrosis in patients with connective tissue disease associated interstitial lung diseases","volume":"187","author":"Chiu","year":"2021","journal-title":"Respir Med"},{"key":"2025100315132778900_keaf306-B6","doi-asserted-by":"crossref","first-page":"2103187","DOI":"10.1183\/13993003.03187-2021","article-title":"Progressive pulmonary fibrosis: an expert group consensus statement","volume":"61","author":"Rajan","year":"2023","journal-title":"Eur Respir J"},{"key":"2025100315132778900_keaf306-B7","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1007\/s10067-023-06570-3","article-title":"Prediction of progressive pulmonary fibrosis in patients with anti-synthetase syndrome-associated interstitial lung disease","volume":"42","author":"Fu","year":"2023","journal-title":"Clin Rheumatol"},{"key":"2025100315132778900_keaf306-B8","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1590\/S1806-37132011000100015","article-title":"Myositis-related interstitial lung disease and antisynthetase syndrome","volume":"37","author":"Solomon","year":"2011","journal-title":"J Bras Pneumol"},{"key":"2025100315132778900_keaf306-B9","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1148\/radiol.2462070712","article-title":"Fleischner society: glossary of terms for thoracic imaging","volume":"246","author":"Hansell","year":"2008","journal-title":"Radiology"},{"key":"2025100315132778900_keaf306-B10","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2025100315132778900_keaf306-B11","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","article-title":"An official American Thoracic Society\/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias","volume":"188","author":"Travis","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"2025100315132778900_keaf306-B12","doi-asserted-by":"crossref","first-page":"2401575","DOI":"10.1183\/13993003.01575-2024","article-title":"Generalisability of pharmaceutical randomised controlled trial eligibility criteria for progressive pulmonary fibrosis","volume":"65","author":"Khor","year":"2025","journal-title":"Eur Respir J"},{"key":"2025100315132778900_keaf306-B13","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N Engl J Med"},{"key":"2025100315132778900_keaf306-B14","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41572-021-00321-x","article-title":"Idiopathic inflammatory myopathies","volume":"7","author":"Lundberg","year":"2021","journal-title":"Nat Rev Dis Primer"},{"key":"2025100315132778900_keaf306-B15","doi-asserted-by":"crossref","first-page":"e003121","DOI":"10.1136\/rmdopen-2023-003121","article-title":"Interstitial lung disease with and without progressive fibrosing phenotype in patients with idiopathic inflammatory myopathies: data from a large multicentric cohort","volume":"9","author":"Zanatta","year":"2023","journal-title":"RMD Open"},{"key":"2025100315132778900_keaf306-B16","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1513\/AnnalsATS.201806-362OC","article-title":"Does systemic sclerosis-associated interstitial lung disease burn out? Specific phenotypes of disease progression","volume":"15","author":"Guler","year":"2018","journal-title":"Ann Am Thorac Soc"},{"key":"2025100315132778900_keaf306-B17","doi-asserted-by":"crossref","first-page":"729602","DOI":"10.3389\/fimmu.2021.729602","article-title":"Description and analysis of a novel subtype of the anti-synthetase syndrome characterized by frequent attacks of fever and systemic inflammation in a single-center cohort study","volume":"12","author":"Sun","year":"2021","journal-title":"Front Immunol"},{"key":"2025100315132778900_keaf306-B18","doi-asserted-by":"crossref","first-page":"1404828","DOI":"10.3389\/fimmu.2024.1404828","article-title":"Prognostic significance of natural killer cell depletion in predicting progressive fibrosing interstitial lung disease in idiopathic inflammatory myopathies","volume":"15","author":"Shao","year":"2024","journal-title":"Front Immunol"},{"key":"2025100315132778900_keaf306-B19","doi-asserted-by":"crossref","first-page":"845988","DOI":"10.3389\/fimmu.2022.845988","article-title":"Different multivariable risk factors for rapid progressive interstitial lung disease in anti-MDA5 positive dermatomyositis and anti-synthetase syndrome","volume":"13","author":"Zuo","year":"2022","journal-title":"Front Immunol"},{"key":"2025100315132778900_keaf306-B20","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1007\/s10067-022-06089-z","article-title":"Tumor markers are associated with rapidly progressive interstitial lung disease in adult-dermatomyositis","volume":"41","author":"Wang","year":"2022","journal-title":"Clin Rheumatol"},{"key":"2025100315132778900_keaf306-B21","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1016\/j.chest.2020.04.066","article-title":"Circulating plasma biomarkers of survival in antifibrotic-treated patients with idiopathic pulmonary fibrosis","volume":"158","author":"Adegunsoye","year":"2020","journal-title":"Chest"},{"key":"2025100315132778900_keaf306-B22","doi-asserted-by":"crossref","first-page":"102774","DOI":"10.1016\/j.jaut.2021.102774","article-title":"Cell surface-expressed Ro52\/IgG\/HLA-DR complex is targeted by autoantibodies in patients with inflammatory myopathies","volume":"126","author":"Arase","year":"2022","journal-title":"J Autoimmun"},{"key":"2025100315132778900_keaf306-B23","doi-asserted-by":"crossref","first-page":"112403","DOI":"10.1016\/j.intimp.2024.112403","article-title":"Peripheral Th17\/Treg imbalance in Chinese patients with untreated antisynthetase syndrome associated interstitial lung disease","volume":"138","author":"Wang","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"2025100315132778900_keaf306-B24","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.rmed.2017.10.020","article-title":"Clinical characteristics of patients with anti-aminoacyl-tRNA synthetase antibody positive idiopathic interstitial pneumonia","volume":"132","author":"Yura","year":"2017","journal-title":"Respir Med"},{"key":"2025100315132778900_keaf306-B25","doi-asserted-by":"crossref","first-page":"804034","DOI":"10.3389\/fimmu.2022.804034","article-title":"Single-cell transcriptomics reveals peripheral immune responses in anti-synthetase syndrome-associated interstitial lung disease","volume":"13","author":"Zhu","year":"2022","journal-title":"Front Immunol"},{"key":"2025100315132778900_keaf306-B26","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.1093\/rheumatology\/keaa266","article-title":"The characteristics of lymphocytes in patients positive for anti-MDA5 antibodies in interstitial lung disease","volume":"59","author":"Huang","year":"2020","journal-title":"Rheumatology"},{"key":"2025100315132778900_keaf306-B27","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ejrad.2014.11.026","article-title":"Interstitial lung disease in anti-synthetase syndrome: initial and follow-up CT findings","volume":"84","author":"Debray","year":"2015","journal-title":"Eur J Radiol"},{"key":"2025100315132778900_keaf306-B28","doi-asserted-by":"crossref","first-page":"5349","DOI":"10.1007\/s00330-019-06152-5","article-title":"Prognostic factors of interstitial lung disease progression at sequential HRCT in anti-synthetase syndrome","volume":"29","author":"Liu","year":"2019","journal-title":"Eur Radiol"},{"key":"2025100315132778900_keaf306-B29","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3899\/jrheum.181141","article-title":"Evolution of pulmonary function in a cohort of patients with interstitial lung disease and positive for antisynthetase antibodies","volume":"47","author":"Gonz\u00e1lez-P\u00e9rez","year":"2020","journal-title":"J Rheumatol"},{"key":"2025100315132778900_keaf306-B30","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1159\/000488358","article-title":"Predictive factors for the long-term deterioration of pulmonary function in interstitial lung disease associated with anti-aminoacyl-tRNA synthetase antibodies","volume":"96","author":"Yamakawa","year":"2018","journal-title":"Respiration"},{"key":"2025100315132778900_keaf306-B31","doi-asserted-by":"crossref","first-page":"4746","DOI":"10.1007\/s00330-023-09439-w","article-title":"Antisynthetase syndrome-related interstitial lung disease (ASyS-ILD): longitudinal imaging findings","volume":"33","author":"Wu","year":"2023","journal-title":"Eur Radiol"},{"key":"2025100315132778900_keaf306-B32","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.autrev.2018.07.013","article-title":"Treatment of idiopathic inflammatory myositis associated interstitial lung disease: a systematic review and meta-analysis","volume":"18","author":"Barba","year":"2019","journal-title":"Autoimmun Rev"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf306\/63427259\/keaf306.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/10\/5379\/63427259\/keaf306.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/10\/5379\/63427259\/keaf306.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T19:13:37Z","timestamp":1759518817000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/10\/5379\/8155854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,3]]},"references-count":32,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,6,3]]},"published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf306","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,6,3]]}}}